Wells Fargo analyst David Maris updated his estimates for Bausch Health in the wake of the company's recent Q2 report, which he said further supported his negative outlook on the stock. Organic growth was down quarter-over-quarter and without the impact of higher prices Bausch Health's revenues would have declined in Q2, Maris stated. The analyst also said that Bausch "may not come close" to hitting its goal of organically adding $700M or more in revenue in its Ortho Dermatologics business in the next three years. Maris, who lowered his 2019 EPS estimate to $4.43 from $5.00 to account for lower gross margins and higher spending estimates, keeps a $9 price target and Underperform rating on Bausch Health shares.